Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants by Klein, N.S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/203316
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Cost-effectiveness, cost-utility and the budget
impact of antidepressants versus preventive
cognitive therapy with or without tapering
of antidepressants
Nicola S. Klein, Ben F. M. Wijnen, Joran Lokkerbol, Erik Buskens, Hermien J. Elgersma,
Gerard D. van Rijsbergen, Christien Slofstra, Johan Ormel, Jack Dekker, Peter J. de Jong,
Willem A. Nolen, Aart H. Schene, Steven D. Hollon, Huibert Burger and Claudi L. H. Bockting
Background
As depression has a recurrent course, relapse and recurrence
prevention is essential.
Aims
In our randomised controlled trial (registered with the
Nederlands trial register, identifier: NTR1907), we found that
adding preventive cognitive therapy (PCT) to maintenance anti-
depressants (PCT+AD) yielded substantial protective effects
versus antidepressants only in individuals with recurrent
depression. Antidepressants were not superior to PCT while
tapering antidepressants (PCT/−AD). To inform decision-makers
on treatment allocation, we present the corresponding cost-
effectiveness, cost-utility and budget impact.
Method
Data were analysed (n = 289) using a societal perspective with
24-months of follow-up, with depression-free days and quality-
adjusted life years (QALYs) as health outcomes. Incremental
cost-effectiveness ratios were calculated and cost-effectiveness
planes and cost-effectiveness acceptability curves were derived
to provide information about cost-effectiveness. The budget
impact was examined with a health economic simulation model.
Results
Mean total costs over 24 months were €6814, €10 264 and
€13 282 for AD+PCT, antidepressants only and PCT/−AD,
respectively. Compared with antidepressants only, PCT+AD
resulted in significant improvements in depression-free days but
not QALYs. Health gains did not significantly favour antidepres-
sants only versus PCT/−AD. High probabilities were found that
PCT+AD versus antidepressants only and antidepressants only
versus PCT/−AD were dominant with low willingness-to-pay
thresholds. The budget impact analysis showed decreased
societal costs for PCT+AD versus antidepressants only and for
antidepressants only versus PCT/−AD.
Conclusions
Adding PCT to antidepressants is cost-effective over 24 months
and PCT with guided tapering of antidepressants in long-term
users might result in extra costs. Future studies examining costs
and effects of antidepressants versus psychological interven-
tions over a longer period may identify a break-even point where
PCT/−AD will become cost-effective.
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Major depressive disorder (MDD) is a highly prevalent and disabling
disorder1 characterised by a recurrent nature.2 Besides the substantial
disability burden, MDD poses considerable financial consequences
because of healthcare use and productivity losses.3 To reduce the dis-
ability and economic burden of MDD, it is important to focus on
strategies that are effective in preventing relapse/recurrence (further
referred to as recurrence).4 Antidepressants are a widely used
relapse prevention strategy and protect against recurrence, with
odds ratios ranging between 0.30 and 0.48 compared with discontinu-
ing antidepressants and switching to placebo (for meta-analyses, see
Borges et al, Geddes et al, Glue et al and Kaymaz et al5–8). However,
non-adherence is common9 and 75% of individuals favour psycho-
logical interventions over antidepressants.10 In past decades, the
effectiveness of psychological relapse prevention strategies for
MDD has been substantiated.4 However, economic research has
not kept pace with the development of relapse prevention strategies.
The increased emphasis on evidence-based psychiatry coincides with
a need to examine and document the wider societal costs and benefits
of treatments to inform decisions regarding allocation and reim-
bursement of treatments in mental healthcare.
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In the Disrupt the Rhythm of Depression (DRD) trial (regis-
tered with the Nederlands trial register, identifier: NTR1907),11
we found that adding preventive cognitive therapy (PCT) to
maintenance antidepressants (PCT+AD) resulted in a statistically
significant risk reduction in terms of time-related proportion of
individuals with depressive recurrence compared with maintenance
antidepressants only. We could not demonstrate that antidepres-
sants reduced the risk of recurrence more compared with PCT
with guided tapering of antidepressants (PCT/−AD).12 The aim
of the current study was to perform cost-effectiveness, cost-utility
and budget impact analyses alongside the DRD trial.
Method
Study design
The DRD trial is a single-blind multicentre three-arm randomised
controlled trial.11 The economic evaluation was performed accord-
ing to the Dutch guidelines13 and reported according to the
Consolidated Health Economic Evaluation Reporting Standards
statement.14 The study was approved by an independent medical
ethics committee (METIGG) and described in detail elsewhere.11,12
Participants and procedure
Participants were recruited via general practitioners, pharmacists,
secondary mental healthcare and the media. To be included, parti-
cipants had to have experienced at least two prior major depressive
episodes, had been in remission for at least 8 weeks but no longer
than 2 years based on DSM-IV criteria as assessed by the
Structured Clinical Interview for DSM-IV Axis-I Disorders
(SCID-I)15 and have a score on the Hamilton Rating Scale for
Depression16 of ≤10. For the full definition of relapse/recurrence
and remission/recovery see supplementary File 1 available at
https://doi.org/10.1192/bjp.2018.81. Participants must have used
maintenance antidepressants for at least 6 months. Exclusion cri-
teria were (hypo)mania or a psychotic disorder/MDD with psych-
otic features, current alcohol or drug misuse, organic brain
damage, a predominant anxiety disorder or psychotherapy more
than twice a month. Because individuals with various depressive
episodes over a longer time span also benefit from relapse preven-
tion strategies,4 we discarded our initial criterion that both major
depressive episodes must have occurred within the past 5 years.
In addition, PCT was initially offered in groups but we extended
this to individual sessions during the trial since many participants
were not able to attend the group meetings because of practical
concerns.
Randomisation
After obtaining informed consent, participants were randomised to
PCT+AD, antidepressants only or PCT/−AD by an independent
research assistant not otherwise involved in the study using auto-
mated stratified permuted block randomisation with computer-
generated random numbers (allocation ratio 10:10:8, respectively).
The randomisation was stratified by number of previous major
depressive episodes (two versus three or more) and baseline care
(general practitioner versus secondary mental healthcare).
Participants were informed about their treatment allocation by a
research assistant not involved in the follow-up interviews.
Independent assessors masked to treatment allocation conducted
the follow-up interviews.
Interventions
PCT is a treatment strategy that is effective in preventing recurrence
in individuals in remission with recurrent depression17–21 and
targets potential cognitive vulnerability factors of MDD. It consists
of eight manualised individual or group sessions performed by
trained psychologists. Issues with therapist adherence were dis-
cussed and resolved during supervision meetings. An independent
research assistant assessed therapist adherence to the treatment
manual and adherence was judged to be high (87%, range: 81–95,
for details, see Bockting et al12). In the two antidepressant continu-
ation groups, general practitioners and psychiatrists were advised to
continue prescribing antidepressants at the minimal required
adequate dosage or higher (≥20 mg fluoxetine equivalent) and in
the tapering group to taper the participants’ antidepressant within
4 weeks. Participants’ adherence to the randomised condition is
described in detail elsewhere.12 In short, adherence to PCT (i.e.
completing at least five sessions) was 88% in the PCT+AD group
and 90% in the PCT/−AD group. Adherence to antidepressants
was monitored with the Trimbos and iMTA questionnaire on
costs associated with psychiatric illness (TiC-P).22 Most (60%) indi-
viduals in the PCT/−AD group tapered their ADs over 6 months. At
6 months, adherence to antidepressants was 58% in the antidepres-
sants-only group, 60% in PCT/−AD group and 65% in the
PCT+AD group.
Economic evaluation
Costs
In accordance with the Dutch guidelines, we used a societal perspec-
tive in this economic evaluation, in which all costs inside and
outside the healthcare sector were assessed. We used the TiC-P,22
which is a reliable and valid self-report instrument for collecting
cost data,23 to prospectively assess the costs. The TiC-P was
designed to refer to the past 3 months and was administered at base-
line and subsequently at 3-month intervals, with the exception of
the last assessment which had a 9-month interval. For the costs in
this 9-month interval we therefore took the costs of the past 3
months multiplied by three. In addition, the maximum number of
days medicated was only 28 and therefore we extrapolated all medi-
cation use to 3 months.
Costs within the healthcare sector were related to a range of
healthcare services participants used during the study, including
medication and in-patient stays, and out-patient and primary care
appointments. Costs related to PCT included training and supervi-
sion of therapists, costs of contacts between participants and thera-
pists and costs of the workbooks used by participants. Patient and
family costs included informal care (i.e. the monetary valuation of
time invested by relatives or acquaintances in assisting the partici-
pant), travel expenses associated with healthcare visits and (psychi-
atric) home care. Informal care was measured as part of the TiC-P,
by asking participants to express the number of hours per week they
received care from relatives and/or friends. This was then valued
using the proxy good method (i.e. time spent on caregiving was
valued at the (labour) market price of a close substitute, in this
case housekeeping). Productivity losses were quantified and
included absence from work (absenteeism), reduced productivity
while at work (presenteeism) and productivity losses of unpaid
work. We used the friction cost method to estimate costs associated
with productivity losses as a result of illness-related absence from
work.24 To promote comparisons with other economic evaluations,
Dutch standard prices25 were used as unit prices. We estimated true
costs of used resources when standard prices were not available. All
unit prices were based on the price level of the Euro in 2015.
Reference prices established for previous years were adjusted to
2015 prices applying the consumer price index.
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Outcomes
The health outcome of the cost-effectiveness analysis was the
number of depression-free days over a period of 24 months based
on DSM-IV criteria assessed with the SCID-I by masked inter-
viewers after 3, 9, 15 and 24 months. Quality-adjusted life-years
(QALYs) over 24 months was the health outcome measure in the
cost-utility analysis and represent disease burden by combining
quality (expressed in utilities) and quantity of life, where one
QALY represents 1 year of perfect health. We used utilities,
derived from the EQ-5D-3L that measures health-related quality
of life,26 to calculate QALYs with the area under the curve
method. These utilities were calculated with Dutch tariffs to
obtain utilities for specific health states.27 Costs and health out-
comes were discounted in accordance with current Dutch guidelines
(1.5% health outcomes, 4% costs).25
Statistical analyses
This study was conducted alongside a clinical trial and the power
calculation of the primary outcome is provided elsewhere.11 This
power calculation was based on detecting a difference in the time-
related proportion of individuals with depressive recurrence
regarding the following comparisons: (a) adding PCT to antidepres-
sants versus antidepressants only; and (b) antidepressants only
versus PCT while tapering antidepressants. Given that the study
was only powered to detect a difference in a depression-related
outcome and not in costs, we used probabilistic and medical deci-
sion-making techniques to draw inferences about cost-effectiveness.
Conforming to the trial protocol, the analyses in this manuscript
were restricted to examine these two comparisons with as primary
analysis a cost-effectiveness analysis using depression-free days as
the health outcome and as the secondary analysis a cost-utility ana-
lysis using QALYs as the health outcome.
We used the intention-to-treat principle, in which all partici-
pants were included in the analyses regardless of adherence to the
randomised interventions. To deal with missing data, multiple
imputations by chained equations with predictive mean matching,
which is recommended for dealing with missing data in (cost-effect-
iveness) trials28,29 were used in our main analysis, incorporating
baseline variables predictive of outcome and drop-out. Multiple
imputations were used to make optimal use of the available data
and reduce possible selection bias because of non-random drop-
out. Costs and outcomes associated with each treatment condition
were used to calculate the incremental cost-effectiveness ratio
(ICER) relative to an alternative.30 The formula of the ICER is:
ICER ¼ (CPCTþAD  CAD)ðQALYPCTþAD QALYADÞ
where CPCT+AD is the mean costs in the PCT+AD group; CAD is the
mean costs in the antidepressants-only group; QALYPCT+AD is the
mean QALYS in the PCT+AD group and QALYAD is the mean
QALYS in the antidepressants-only group.
The bootstrap method31 was used for information about the
uncertainty of the results. To allow correlated residuals and
correct for differences in baseline characteristics in sensitivity ana-
lyses, seemingly unrelated regression equations were bootstrapped
5000 times. Simulated values of the estimates for cost and
outcome differences were displayed in a cost-effectiveness plane32
to capture the uncertainty in the ICER estimate. Information
about the cost-effectiveness plane can be found in supplementary
File 2. Cost-effectiveness acceptability curves (CEACs)33 were
derived that inform decision-makers about the probability that an
intervention will be cost-effective, depending on the willingness to
pay per additional unit of health outcome.
Both complete cost and effect data were available for 105 parti-
cipants. For 169 participants at least 50% of the cost data and for 175
at least 50% of the QALY data were available during the 24 months.
For 197 participants follow-up data on depression-free days were
available. We performed several sensitivity analyses to examine
the robustness of our results. The intervention could not be
started and follow-up data were not available for 43 participants
in the PCT groups for practical reasons. In addition, 16 participants
in the PCT groups and 21 in the antidepressants-only group
dropped out immediately after randomisation for other reasons.
Ultimately, 209 participants had follow-up data and were used in
our main analysis. We included all 289 participants in a sensitivity
analysis.
Furthermore, we repeated the analyses in participants with at
least 50% cost data available and in complete cases.We also repeated
the main analysis while correcting for baseline costs and utilities, for
whether participants filled out additional momentary assessments,
and for whether participants in the therapy groups received the
individual or group therapy. Finally, our results for the primary out-
comes suggested an increased recurrence rate for PCT/−AD com-
pared with antidepressants only in the first 140 days.12 To
account for possible withdrawal symptoms in the first months, we
performed an analysis taking into account only the final 1.5 years
of the study.
Budget impact analysis
We used a health economic simulation model for depression,
DEPMOD,34 to examine the budget impact when offering the differ-
ent relapse prevention strategies to an estimated 25% of the target
population in the Netherlands. Per-person cost differences as esti-
mated by the trial data were applied to 25% of the target group to
estimate the order of magnitude of the budget impact. The budget
impact was estimated both from a healthcare perspective and a
societal perspective, and considered a 2-year time horizon.
Results
Details of the participant flow have been described elsewhere12
Between 14 July 2009 and 30 April 2015, 289 participants were
assessed for eligibility and randomised to the PCT+AD (n = 104),
antidepressants-only (n = 100) or PCT/−AD (n = 85) groups. Of
those, 209 provided additional data following randomisation.
Demographic and clinical variables are displayed in Table 1. The
participants in the treatment groups appeared to have similar char-
acteristics, except for slight imbalances in marital status, education
and employment status. Since baseline characteristics of all partici-
pants and the participants with any follow-up data were similar and
equally distributed over the treatment groups, no indication for a
systematic bias because of drop-out was found.
Costs
The various types of costs generated by the three groups and infor-
mation on the use of healthcare services during the 24months of the
study are presented in supplementary Table 1. Costs are based on
the data of participants for whom at least one cost measurement
was available during follow-up. Mean costs per participant directly
related to PCT were €349, €354, and €0 in the PCT+AD, PCT/−AD
and antidepressants-only groups, respectively. These costs mainly
consisted of costs related to training/supervision of therapists and
contacts between participants and therapists. Hospital admissions
and care provided by mental healthcare institutions contributed
considerably to overall costs within the healthcare sector. Costs
associated with productivity losses were substantial.
Cost-effectiveness of relapse prevention strategies for depression
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When visually inspecting supplementary Table 1, in most
categories costs appear slightly lower for the PCT+AD group com-
pared with the antidepressants-only group and the antidepressants-
only group compared with the PCT/−AD group except for larger
reductions for PCT+AD compared to antidepressants-only regard-
ing absenteeism and hospital admissions.
An overview of the mean costs per measurement for all 209
individuals is displayed in supplementary Table 2. Mean total
costs of the PCT+AD group appear lower than in the two other
groups at each measurement period, except for the first measure-
ment (0–3 months). Mean total costs for the antidepressants-only
group compared with the PCT/−AD group appear only higher
between 3 and 9 months and lower during the other measurements.
Accumulating all costs (supplementary Table 2), mean total costs
during the 24 months of the study were €6814 for the PCT+AD
group, €10 264 for the antidepressants-only group and €13 282
for the PCT/−AD group.
Effects
Themean number of depression-free days within 24months follow-
up was 628 (range 187–730) for the antidepressants-only group, 607
(range 51–730) for the PCT/−AD group and 662 (range 194–730)
for the PCT+AD group. A statistically significant difference in
depression-free days was found for the PCT+AD group compared
with the antidepressants-only group (P = 0.016). The difference in
depression-free days for the antidepressants-only group compared
with the PCT/−AD group was not statistically significant (P =
0.637). Mean QALYs over 24 months were 1.62 (range 0.95–1.95)
for the PCT+AD group, 1.64 (range 1.00–1.99) for the antidepres-
sants-only group and 1.59 (range 0.64–1.94) for the PCT/−AD
group. No statistically significant differences in QALYs were
found between the PCT+AD group compared with the
antidepressants-only group (P = 0.907) and the antidepressants-
only group compared with the PCT/−AD group (P = 0.628).
Economic evaluation
The results of the main analyses are presented in Table 2. Table 2
and the cost-effectiveness plane (Fig. 1) show that regarding depres-
sion-free days, most (93.1%) of the bootstrapped ICERs were
located in the south-east quadrant, indicating a 93.1% probability
that costs were lower and health outcomes better for PCT+AD com-
pared with the antidepressants-only group (i.e. PCT+AD is domin-
ant). The CEAC in Fig. 1 regarding depression-free days shows a
high probability that PCT+AD is dominant. Regarding QALYs,
PCT+AD was associated with 67.8% of the bootstrapped ICERs
appearing in the south-west quadrant, indicating that costs were
lower and health outcomes worse compared with antidepressants
only (Table 2 and Fig. 1). Interpretation of outcomes located in
the south-west quadrant depends on whether decision-makers are
willing to accept a cost reduction for a loss in health. The CEAC
in Fig. 1 regarding QALYs shows a high probability that
PCT+AD dominates antidepressants only when the willingness-
to-accept threshold is low and a decreasing probability if the thresh-
old to accept a reduction in health is increased.
Regarding antidepressants only compared with PCT/−AD,
Table 2 and the cost-effectiveness planes (Fig. 2) show that most
(72.9% for depression-free days and 80.8% for QALYs) of the boot-
strapped ICERs were located in the south-east quadrant, indicating
a 72.9% and 80.8% probability that antidepressants only generated
lower costs and better outcomes compared with PCT/−AD (i.e.
antidepressants only is dominant). The CEACs in Fig. 2 show that
the probability that antidepressants only are dominant compared
with PCT/−AD is approximately 90% for both depression-free
days and QALYs when the willingness to pay per additional
Table 1 Demographics and clinical variables
PCT+AD group (n = 104) Antidepressants-only group (n = 100) PCT/–AD group (n = 85)
Age, years:a mean (s.d.) 47.0 (9.3) 47.2 (10.5) 47.7 (11.1)
Gender, women: n (%) 72 (69) 64 (64) 53 (62)
Dutch nationality,b n (%) 101 (97) 95/99 (96) 82/84 (98)
Marital status,b n (%)
Single 27/103 (26) 32/99 (32) 28/84 (33)
Married/cohabiting 69/103 (67) 59/99 (60) 46/84 (55)
Divorced/widowed 7/103 (7) 8/99 (8) 10/84 (12)
Education,b n (%)
Primary and/or secondary education 20 (19) 25/99 (25) 12/84 (14)
Vocational education 31 (30) 28/99 (28) 23/84 (27)
Higher education 53 (51) 46/99 (46) 49/84 (58)
Employed,b n (%) 73/103 (71) 65/98 (66) 53/84 (63)
Treatment as usual, n (%)
Specialised mental healthcare 32 (31) 31 (31) 26 (31)
General practitioner 72 (69) 69 (69) 59 (69)
Number of depressive episodes, median (IQR) 5 (3–6) 4 (3–6) 5 (3–6)
Total HRSD, mean (s.d.) 3.6 (3.1) 3.8 (3.1) 3.6 (3.0)
Total IDS-SR, mean (s.d.) 20.4 (11.5) 18.5 (10.8) 20.6 (12.1)
Type of antidepressant,b n (%)
SSRI 85/103 (83) 79/99 (80) 69/85 (81)
SNRI 1/103 (1) 8/99 (8) 1/85 (1)
Tricyclic antidepressant 7/103 (7) 7/99 (7) 10/85 (12)
Atypical antidepressant 5/103 (5) 2/99 (2) 3/85 (4)
Monoamine oxidase inhibitor 0 (0) 1/99 (1) 0 (0)
More than one antidepressant 5/103 (5) 2/99 (2) 2/85 (2)
EQ-5D-3L,c mean (s.d.) 0.84 (0.16) 0.80 (0.18) 0.79 (0.17)
Baseline costs,c €: mean (s.d.) 1533 (5423) 1695 (3049) 1778 (3383)
PCT + AD, preventive cognitive therapy and antidepressants; PCT/–AD, preventive cognitive therapy with guided tapering of antidepressants; IQR, interquartile range; HRSD, Hamilton Rating
Scale for Depression; IDS-SR, Inventory of Depressive Symptomatology Self-Report; SSRI, selective serotonin reuptake inhibitor; SNRI, selective serotonin and norepinephrine reuptake
inhibitor.
a Two participants were older than 65 years at baseline (i.e. 67 and 68 years).
b Data not available for all randomised participants.
c Imputed data.
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health gain is zero and the probability for depression-free days
slightly decreases and for QALYs slightly increases with additional
investments. The sensitivity analyses yielded similar results. When
only taking into account the last 1.5 years of the study to examine
the cost-effectiveness of antidepressants only compared with
PCT/−AD, the gain in depression-free days decreased from 21 to
12 but antidepressants only remained cost-effective compared
with PCT/−AD.
Budget impact analysis
The target population size in the Netherlands in a given year,
meaning the yearly prevalence of people with at least two previous
episodes of depression, was estimated to be 110 000, which is
roughly 1% of the total population of approximately 10 million
people aged between 18 and 65 in the Netherlands. Offering
PCT+AD instead of antidepressants alone to 25% of the target
population is associated with an estimated decrease in costs of 76
million euro from a healthcare perspective and 95 million euro
from a societal perspective. Offering antidepressants alone instead
of PCT/−AD to 25% of the target population is associated with
an estimated decrease in costs of 9.5 million euro from a healthcare
perspective and 83 million euro from a societal perspective.
Discussion
Adding PCT to antidepressants had the highest number of depres-
sion-free days and lowest costs, PCT/−AD had the lowest number
of depression-free days and highest costs, and antidepressants
only ranked in-between in terms of depression-free days and
costs. Adding PCT to antidepressants was dominant compared
with antidepressants only regarding depression-free days and
resulted in decreased costs at a population level whereas antide-
pressants only dominated PCT/−AD in the cost-effectiveness,
cost-utility and budget impact analyses.
Adding PCT to antidepressants compared with
antidepressants only
Although adding PCT to antidepressants was dominant compared
with antidepressants only resulting in an increase (statistically sig-
nificant) in depression-free days and decrease in costs, QALYs did
not significantly differ for PCT+AD compared with antidepressants
only. The EQ-5D used in our study might lack sensitivity to detect
small improvements in individuals in remission with recurrent
MDD. Moreover, it only displays the current health state and there-
fore does not capture all recurrences during the 24 months of the
study. Studies indeed suggest that the EQ-5D might be less repre-
sentative for individuals with psychiatric symptoms.35 Therefore,
also in line with the trial protocol, we consider the cost-effectiveness
analysis using depression-free days as the primary outcome.
The finding that PCT+AD dominated antidepressants only
in terms of depression-free days contrasts with another Dutch
relapse prevention study where adding mindfulness-based cognitive
therapy to maintenance antidepressants did not reduce the risk of
recurrence compared with antidepressants only.36 However, it is
congruent with studies demonstrating that sequential cognitive
therapy after remission is protective of recurrence37 and with our
primary outcomes.12 Moreover, our finding is partly in line with a
cost-effectiveness study of a relapse prevention strategy for partially
remitted depression that found cognitive therapy added to antide-
pressants and clinical management was likely to be cost-effective
compared with antidepressants and clinical management only
over 17 months when decision-makers were willing to pay £4500
per recurrence prevented,38 and with a cost-effectiveness study
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regarding a relapse prevention strategy for individuals in (partial)
remission using maintenance antidepressants that found family
psychoeducation added to treatment as usual was highly likely to
be cost-effective compared with treatment as usual over 9 months
if a depression-free day would be valued at $20 or more.39 In both
studies, only direct healthcare costs were taken into account.
Karyotaki et al40 performed a systematic review of economic
evaluations alongside randomised controlled trials for depression
treatments. Three trials were identified comparing the combination
of a psychological intervention and antidepressants versus anti-
depressant only and inconsistent results were found. Overall,
Karyotaki et al40 concluded that studies likely varied widely in
results because of differences in study design and study population
and that there remain important gaps in knowledge regarding eco-
nomic evaluations for MDD treatments. Our study is the first to
examine the economic consequences of adding a psychological
intervention to maintenance antidepressants in individuals who
are recurrently depressed and it shows promising results. More
studies are needed to substantiate this finding.
Antidepressants only compared with PCT while
tapering antidepressants
Health outcomes did not significantly favour antidepressants only
compared with PCT/−AD, which is in line with our primary
outcome.12 However, the cost-effectiveness plane showed that anti-
depressants only dominated PCT/−AD as most of the bootstrapped
ICERs were located in the south-east quadrant where costs are lower
and health outcomes better. Antidepressants only also resulted in
lower societal costs in the budget impact analysis. These findings
are only partly consistent with the findings of two studies examining
the (cost)effectiveness of a relapse prevention strategy (mindful-
ness-based cognitive therapy) with support to taper off maintenance
antidepressants compared with maintenance antidepressants only
in individuals in remission from recurrent depression.41,42 In one
study, antidepressants dominated mindfulness-based cognitive
therapy with tapering support when the willingness-to-pay thresh-
old was zero per additional recurrence prevented but this reversed
when the willingness to pay increased to $1000 and above.41
Results of the other study also suggested that an improvement in
terms of recurrence was achieved at higher costs for mindfulness-
based cognitive therapy while tapering antidepressants compared
with antidepressants only, but that antidepressants dominated
mindfulness-based cognitive therapy while tapering antidepressants
in terms of QALYs. The probability that mindfulness-based cogni-
tive therapy was cost-effective compared with antidepressants did
not rise above 52% regardless of effect measure.42
As also stated in the DRD study,12 it is important to examine
why the results were not better for PCT/−AD compared with anti-
depressants only, whereas the addition of PCT to antidepressants
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Fig. 1 Incremental cost-effectiveness planes ((a) and (c)) and cost-effectiveness acceptability curves ((b) and (d)) for costs per depression-free
day ((a) and (b)) and costs per quality-adjusted life-years (QALYs) gained ((c) and (d)) for preventive cognitive therapy plus antidepressants
compared with antidepressants only.
Based on 5000 bootstrapped cost-effectiveness pairs. Reps, bootstrap replication; PE-line, line that represents the point estimate of the incremental cost-effectiveness ratio
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resulted in additional protection. One explanation might be a tem-
porary imbalance caused by withdrawal of antidepressants. The sys-
tematic review of Fava et al43 suggests that withdrawal symptoms
can take many forms and that they usually occur within a few
days or weeks but can also persist for a longer period (i.e. up to 1
year). This corroborates the DRD study, where we found a higher
risk of recurrence during the first 140 days gradually disappearing
thereafter in participants tapering antidepressants with PCT com-
pared with antidepressant only.12 However, when correcting for
this possible destabilisation in the current study, the gain in depres-
sion-free days for antidepressants only decreased but costs
remained lower and effects slightly better for antidepressants only
compared with PCT/−AD. It should be noted that most participants
(60%) tapered their antidepressants within 6 months, indicating
that the advised 4 weeks is not feasible for many and that possible
withdrawal effects may have occurred later during the study.
A second explanation might be that participants had difficulty
tapering off antidepressants, resulting in a cycling on and off antide-
pressants that has shown to generate high costs44 and might result in
progressive tolerance to antidepressants.45 A third explanation might
be that prolonged use of antidepressants results in oppositional toler-
ance, heightening the recurrence risk after discontinuation.46
In the long term, we expect costs and outcomes to be more
promising for PCT/−AD compared with antidepressants only as
costs of antidepressants will be reduced, and outcomes will be
enhanced because of the enduring effects of PCT up to 10
years.4,18 This is also in line with two cost-effective modelling
studies in episodic andmaintenanceMDD that showedmaintenance
cognitive–behavioural therapy and antidepressants were both
cost-effective strategies over 5 years, with maintenance cognitive–
behavioural therapy as a favourable option because of their low costs
compared with maintenance antidepressants.47,48 Future studies are
needed to examine at what point in time a break-even point will
appear where costs and outcomes will improve for PCT/−AD.
Limitations
Some limitations have to be acknowledged. First, we collected the
cost and QALY data via online questionnaires that were not manda-
tory, resulting in missing data. We handled missing data using mul-
tiple imputations. Baseline variables predicted whether data were
missing, suggesting data were at least partly missing at random
and that multiple imputations may have reduced bias associated
with complete case analyses. In addition, our sensitivity analyses
suggested that missing data had no substantial influence on the
results. However, a possibility remains that missing data were not
missing at random. Second, this study was not powered to detect
a significant difference in QALYs and costs. Yet, the probabilistic
and medical decision-making techniques we used allowed us to
make estimations of the cost-effectiveness and cost-utility.
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Third, whereas a willingness-to-pay threshold for QALYs is
available, this is not the case for depression-free days. Therefore,
interpretation of the willingness to pay regarding depression-free
days remains speculative. Given that in the current study most out-
comes were located in the south-east quadrant where costs were
lower and effects better, this limitation does not have a major
impact on the implications of this study. Fourth, no pill–placebo
control group or control group for PCT was used, which would
have enabled examination of the specific effects of antidepressants
and PCT. Fifth, the data were collected in the Netherlands and the
study comprised individuals in remission from at least two previous
major depressive episodes usingmaintenance antidepressants, which
might compromise generalisability. Sixth, the estimated budget
impact relies on the assumption that the trial results are generalisable
to a larger population within the Netherlands, which might not be
the case. Nevertheless, we believe that our results can be generalised
as participants were recruited via a wide range of resources and
our inclusion and exclusion criteria regarding comorbidity were
lenient.
Clinical implications and recommendations
For individuals willing to stay on antidepressants, the addition of
PCT provides a substantial benefit over antidepressants only in
terms of cost-effectiveness and the budget impact. For individuals
wishing to taper antidepressants, extra investments might be
required. Since preventive effects of psychological interventions
last up to 10 years4,18 and maintenance antidepressants generate
long-term costs, future studies should examine the cost-effective-
ness of relapse prevention programmes in maintenance antidepres-
sants over a longer time span than the 24 months of the current
study. In addition, future studies should examine how withdrawal
symptoms and specific patterns of discontinuing antidepressants
are associated with cost-effectiveness and whether PCT should be
administered before or after tapering antidepressants.
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